Trastuzumab glyco-optimised - Glycotope

Drug Profile

Trastuzumab glyco-optimised - Glycotope

Alternative Names: Glycooptimised TrastuzuMab-GEX; GT-Mab 7.3-GEX; TrasGEX; TrastuzuMab-GEX

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glycotope
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gastric cancer
  • No development reported Breast cancer

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for phase-I development in Breast-cancer in Austria (IV, Infusion)
  • 24 Jul 2017 Trastuzumab glyco-optimised - Glycotope is available for licensing as of 24 Jul 2017. http://www.glycotope.com/biopharmaceuticals-pipeline/ (Glycotope pipeline, July 2017)
  • 29 Aug 2016 Phase-II clinical trials in Gastric cancer in Germany (IV) (Glycotope pipeline as of August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top